Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
April 20 2021 - 7:00AM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced the
nominations of Sir Michael Rawlins and Joel S. Marcus to stand for
election to the Company’s board of directors at its 2021 annual
meeting of stockholders, scheduled for June 21, 2021. Sir Michael
Rawlins is being nominated as a new independent director of the
board and Joel Marcus is being nominated for re-election to the
board.
“We are excited to announce the nomination of Sir Michael
Rawlins as we look forward to the potential approval of CAPLYTA for
bipolar depression and the Company’s continued growth,” said Dr.
Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Sir
Michael’s extensive regulatory experience and product development
expertise will be beneficial to the Company as we execute on our
strategies for future growth. We are also grateful to Joel Marcus
for his continued service and the strong leadership he
provides.”
Additionally, the Company announced that, effective as of the
2021 annual meeting of stockholders, Dr. Christopher Alafi will
have completed his term as a board member and will no longer serve
as a director for the Company.
About Sir Michael Rawlins GBE M.D., FRCP,
FMedSci
Sir Michael was the chairman of the Medicines and Healthcare
products Regulatory Agency (MHRA) from 2014 to 2020. He previously
served on the Company’s board from 2013 to 2014 until he was
required to resign pursuant to MHRA independence policies in
connection with assuming his leadership role in 2014. He is a
clinical pharmacologist and specialist in internal medicine. He was
the chair of the National Institute for Health and Care Excellence
(NICE) from 1999 to 2013. He was professor of clinical pharmacology
in Newcastle, United Kingdom, and physician at the Newcastle
Hospitals, from 1999 to 2006. He was chairman of the Committee on
Safety of Medicines (1992-1998), chairman of the Advisory Council
on the Misuse of Drugs (1998-2008) and founding chairman of the
National Institute for Clinical Excellence (1999-2013). He is a
past president of the Royal Society of Medicine (2012-2014).
Currently, Sir Michael is an honorary professor at the London
School of Hygiene and Tropical Medicine, and emeritus professor at
the University of Newcastle upon Tyne. Sir Michael was appointed
Knight Grand Cross of the Order of the British Empire (GBE) in
2017. The honor is for services to the safety of medicines,
healthcare and innovation and comes after more than three decades
at the forefront of innovation, development and leadership in the
public health sector.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company
founded on Nobel prize-winning research that allows us to
understand how therapies affect the inner-workings of cells in the
body. The company leverages this intracellular approach to develop
innovative treatments for people living with complex psychiatric
and neurologic diseases.
Additional Information and Where to Find It
Intra-Cellular Therapies, its directors and certain of its
executive officers may be deemed to be participants in the
solicitation of proxies from stockholders in connection with the
matters to be considered at the Intra-Cellular Therapies 2021
annual meeting of stockholders. Intra-Cellular Therapies intends to
file a definitive proxy statement with the U.S. Securities and
Exchange Commission (the “SEC”) in connection with such
solicitation of proxies from stockholders. STOCKHOLDERS ARE
STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT WHEN IT
BECOMES AVAILABLE AS IT WILL CONTAIN IMPORTANT INFORMATION.
Information regarding ownership of Intra-Cellular Therapies stock
and other securities by Intra-Cellular Therapies’ directors and
executive officers is included in their SEC filings on Forms 3, 4
and 5, which can be found through the Intra-Cellular Therapies
website (www.intracellulartherapies.com) in the section “Investors”
or through the SEC’s website at www.sec.gov. Additional information
about Intra-Cellular Therapies’ directors and executive officers
and their interests is set forth in Intra-Cellular Therapies’
Annual Report on Form 10-K for the fiscal year ended December 31,
2020, which was filed with the SEC on February 25, 2021, and
Intra-Cellular Therapies’ definitive proxy statement for its 2021
annual meeting of stockholders, once it is filed with the SEC which
is expected on or about April 29, 2021, and in Intra-Cellular
Therapies other SEC filings, which can be found through
Intra-Cellular Therapies’ website (www.intracellulartherapies.com)
in the section “Investors” or through the SEC’s website at
www.sec.gov. More detailed and updated information regarding the
identity of potential participants, and their direct or indirect
interests, by security holdings or otherwise, will be set forth in
the definitive proxy statement and other materials to be filed with
the SEC in connection with Intra-Cellular Therapies’ 2021 annual
meeting of stockholders. Stockholders will be able to obtain any
proxy statement, any amendments or supplements to the proxy
statement and other documents filed by Intra-Cellular Therapies
with the SEC for no charge at the SEC’s website at www.sec.gov.
Copies will also be available at no charge at Intra-Cellular
Therapies’ website at www.intracellulartherapies.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, our director nominees; the
therapeutic value, clinical and non-clinical development plans,
potential regulatory approval, and commercial potential of our drug
product candidates; and development efforts and plans under the
caption "About Intra-Cellular Therapies." All such forward-looking
statements are based on management's present expectations and are
subject to certain factors, risks and uncertainties that may cause
actual results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include but are not limited to the
following: our current and planned clinical trials or other studies
for our product candidates may not be successful or may take longer
and be more costly than anticipated; product candidates that
appeared promising in earlier research and clinical trials may not
demonstrate safety and/or efficacy in larger-scale or later
clinical trials; our proposals with respect to the regulatory path
for our product candidates may not be acceptable to the FDA;
our reliance on collaborative partners and other third parties for
development of our product candidates; the COVID-19 pandemic may
negatively impact the conduct of, and the timing of enrollment,
completion and reporting with respect to, our clinical trials; any
other impacts on our business as a result of or related to the
COVID-19 pandemic; and the other risk factors detailed in our
public filings with the Securities and Exchange Commission.
All statements contained in this press release are made only as of
the date of this press release, and we do not intend to update this
information unless required by law.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President,
Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc.Lisa
Burnsjgrimaldi@burnsmc.com212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Sep 2023 to Sep 2024